Global market valuation was derived through revenue mapping, procedure volume analysis, and device installation base tracking. The methodology included:
Identification of 35+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America specializing in neuromodulation and VNS technologies
Product mapping across implantable VNS devices, external VNS systems, transcutaneous VNS devices, and wearable neuromodulation technologies
Analysis of reported and modeled annual revenues specific to vagal nerve stimulation portfolios, including device sales, implantation procedures, and recurring revenue from battery replacements and lead revisions
Coverage of manufacturers representing 75-80% of global market share in 2024, including Medtronic, LivaNova, Boston Scientific, Abbott Laboratories, NeuroPace, ElectroCore, and emerging players in non-invasive VNS
Extrapolation using bottom-up (procedure volume × ASP by country/region, implantation rates per 100,000 epilepsy population, replacement cycle analysis) and top-down (manufacturer revenue validation, neuromodulation market allocation) approaches to derive segment-specific valuations across indication, device type, end user, technology, and patient type categories